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Background
Patients with head and neck cancer (HNC) undergoing 
radiotherapy (RT) may experience chronic side effects, such as 
xerostomia and dysphagia, which can have a severe negative 
impact on quality of life (QoL)1. Predicting these symptoms in 
HNC patients is thus of clinical interest, and recent quantitative 
approaches have provided insight into these symptom 
trajectories. 
Our lab recently developed a measure of symptom burden over 
time, the area under the symptom trajectory curve (AUCsymptom or 
AUCs), which condenses symptom data over the course of 
treatment and beyond into a single data point while maintaining 
its temporal nature (Fig 1)2. Previous studies have indicated that 
acute symptoms, particularly xerostomia and dysphagia, strongly 
predict late symptoms3, but this relationship for the AUCs has not 
been established. Further, the ability of the AUCs to identify the 
impacts of specific symptoms on QoL is currently unknown. 
Consequently, our objectives for this study are to expand upon 
our lab’s previous work to determine the predictive value of the 
acute AUCs for late AUCs and to use AUCs data to identify 
symptoms associated with lower patient-reported QoL.
Figure 1. Sample illustration of the area under the symptom trajectory curve 
(AUCsymptom) for several symptom trajectories, adapted from Van Dijk et al.
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The AUCsymptom represents the percentage of area covered by the symptom 
score for a specific interval divided by the maximum potential area. MDASI-HN patient data was retrospectively collected at 
baseline, RT weeks 1-7, and 6-weeks post-RT (acute) 
and between 3-6 months and 18-24 months post-RT 
(late). Patients with both acute and late AUCs <0.15 for a 
particular symptom were excluded from analysis for that 
symptom. Spearman’s rho correlation coefficients and 
linear regressions were calculated between acute and late 
AUCs, and correlations with p-values < 0.05 were 
considered significant. 
Spearman’s rho correlation coefficients between AUCs for 
acute and late MDASI-HN symptoms and AUCs for 
MDASI-HN interference items will then be calculated both 
individually and as a composite (average) interference 
score. Following these steps, the effects of treatment, 
TNM staging, age, and gender on these relationships will 
be evaluated using a non-parametric equivalent of linear 
regression.
Methods
AUCs data from 336 patients from a registry at MD Anderson 
Cancer Center of patients evaluated for a suspected or 
confirmed diagnosis of oropharyngeal cancer (OPC), 
previously calculated by our lab2, was used in the present 
study. AUCs data were originally derived from patient 
responses to the MDASI-HN, a validated, head and neck 
specific, 28-item symptom reporting tool in which patients rate 
symptoms from 0 (none) to 10 (worst imaginable). MDASI 
items are split into core symptoms and interference items, 
which patients use to rate the severity of their symptoms and 
estimate how much their symptoms interfere with normal life 
activities (Fig 2). 
Figure 2. Sample form depicting core and interference items for 
the M.D. Anderson Symptom Inventory (MDASI).5
Symptom Spearman's rho p-value n
dry mouth 0.4708 **** 314
taste 0.4009 **** 312
mucus 0.3203 **** 301
fatigue 0.3142 **** 287
drowsy 0.3114 **** 245
swallow 0.2922 **** 289
appetite 0.2693 **** 280
pain 0.2544 **** 291
mucositis 0.2417 **** 262
sad 0.2191 0.0254* 104
activity 0.1909 0.0041** 224
sleep 0.1804 0.0042** 250
nausea 0.1618 0.0378* 165
enjoy 0.1486 0.0348* 202
work 0.1394 0.0402* 217
skin 0.1213 0.0825 206
constipation 0.1063 0.1566 179
distress 0.08211 0.3245 146
relations 0.05389 0.5332 136
mood 0.04811 0.5213 180
vomit 0.03714 0.7534 74
voice 0.02067 0.7824 181
walking 0.009144 0.9197 124
choke 0.0009205 0.9906 167
sob -0.02445 0.8373 73
memory -0.0311 0.7213 134
numb -0.09869 0.3547 90
teeth -0.144 0.0711 158
Results
So far, correlations between acute and 
late AUCs have been initially calculated. 
At this early stage, acute AUCs does 
appear to be significantly correlated with 
late AUCs for several locoregional 
symptoms, most notably dry mouth 
(Spearman’s rho 0.47, p < 0.0001) and 
taste (Spearman’s rho 0.40, p <0.0001) 
(Fig 3). The relationships between acute 
and late AUCs were also graphed as 
scatter plots and linear regressions were 
calculated; the plot for dry mouth is 
shown below (R2 = 0.24, Fig 4).The next 
steps are to calculate composite 
interference scores, to calculate 
correlations between these scores and 
acute/late symptom AUCs, and finally to 
assess the effects of treatment, staging, 
age, and gender on these relationships.
Figure 3 (right): Heatmap of Spearman’s rho 
correlations between acute AUCs and late AUCs
for each item on the MDASI-HN. P-values < 
0.0001 are reported as extremely significant (****).
Discussion
Although this project is still in progress, preliminary 
evidence suggests the AUCsymptom measure may have 
utility for identifying patients that would benefit from 
individualized RT adaptation, at least for preventing 
chronic locoregional symptoms such as dry mouth, 
taste, and mucus. These symptoms have been shown 
to have a profound negative impact on patient QoL 
especially as they relate to nutrition6; malnutrition is 
common in HNC patients and is associated with lower 
overall survival7. While several acute and late 
symptoms, such as dry mouth, were relatively well 
correlated via Spearman’s rho (0.47), their linear 
relationship was much weaker (R2 = 0.24), suggesting 
that clinical variables such as treatment, staging, or 
age may also be important to the development of late 
symptoms. We expect that our final results including 
these variables, as well as our interference item 
analysis, will provide a more complete picture. 
Figure 3. Scatter plot and linear regression of acute AUCs for a single 
symptom (dry mouth) vs. late AUCs for dry mouth. AUCs values are reported 
as percentages.
Conclusions
While it is premature to draw strong conclusions from 
our work so far, we anticipate that this project will 
demonstrate the validity of the AUCsymptom measure 
and encourage further study of its potential for 
understanding treatment side effects that are most 
important to HNC patients. With further validation,  
AUCsymptom may present an opportunity for clinicians to 
utilize data-driven or algorithmic approaches to provide 
individualized care proactively rather than reactively. In 
addition, while this measure was developed for HNC 
patients, it could easily be adapted for other cancers, 
and could be used to monitor and prevent any number 
of treatment side effects, especially those with well-
known trajectories. Perhaps the AUCsymptom may one 
day become an integral part of the clinician’s toolbox in 
delivering individually personalized, highly effective 
cancer treatment.
References
1. Tyler MA, Mohamed ASR, Smith JB, et al. Long-term quality of life after 
definitive treatment of sinonasal and nasopharyngeal 
malignancies. Laryngoscope. 2020;130(1):86-93. doi:10.1002/lary.27849
2. Dijk LV van, Mohamed ASR, Ferrarotto R, et al. The impact of induction 
and/or concurrent chemoradiotherapy on acute and late patient-reported 
symptoms in oropharyngeal cancer: Application of a mixed-model analysis 
of a prospective observational cohort registry. Cancer. 2021; 127(14):2453-
2464. doi:https://doi.org/10.1002/cncr.33501
3. van der Laan HP, Bijl HP, Steenbakkers RJHM, et al. Acute symptoms 
during the course of head and neck radiotherapy or chemoradiation are 
strong predictors of late dysphagia. Radiotherapy and Oncology. 
2015;115(1):56-62. doi:10.1016/j.radonc.2015.01.019
4. Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and 
neck cancer symptom burden: the development and validation of the M. D. 
Anderson symptom inventory, head and neck module. Head Neck. 
2007;29(10):923-931. doi:10.1002/hed.20602
5. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress 
in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 
2000;89(7):1634-1646. doi:10.1002/1097-0142(20001001)89:7<1634::aid-
cncr29>3.0.co;2-v
6. Mulasi U, Vock DM, Jager-Wittenaar H, et al. Nutrition Status and Health-
Related Quality of Life Among Outpatients With Advanced Head and Neck 
Cancer. Nutr Clin Pract. 2020;35(6):1129-1137. doi:10.1002/ncp.10476
7. Kubrak C, Martin L, Gramlich L, et al. Prevalence and prognostic 
significance of malnutrition in patients with cancers of the head and 
neck. Clin Nutr. 2020;39(3):901-909. doi:10.1016/j.clnu.2019.03.030
Predicting Patient-Reported Outcomes for Oropharyngeal Cancer Patients Treated With 
Radiotherapy: Evaluating the Efficacy of AUCsymptom
Elizabeth E Klettke, BA1, Lisanne V Van Dijk, PhD2,3, Clifton D Fuller MD PhD3
1University of Texas Health Science Center, McGovern Medical School, Houston, Texas 2Department of Radiation Oncology, University Medical Center Groningen, University of 
Groningen, Groningen, Netherlands 3Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
